## John Kim Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3765357/publications.pdf Version: 2024-02-01



Іоны Кім Сног

#	Article	IF	CITATIONS
1	Cytarabine dose reduction in patients with lowâ€risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2022, 69, e29313.	1.5	5
2	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i> /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. Journal of Clinical Oncology, 2022, 40, 2023-2035.	1.6	36
3	Integrative network analysis reveals USP7 haploinsufficiency inhibits E-protein activity in pediatric T-lineage acute lymphoblastic leukemia (T-ALL). Scientific Reports, 2021, 11, 5154.	3.3	10
4	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	5.0	71
5	Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia. Modern Pathology, 2021, 34, 2050-2054.	5.5	5
6	Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia. Clinics in Laboratory Medicine, 2021, 41, 485-495.	1.4	0
7	Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer. JAMA Oncology, 2020, 6, 552.	7.1	77
8	Acute erythroid leukemia is enriched in <i>NUP98</i> fusions: a report from the Children's Oncology Group. Blood Advances, 2020, 4, 6000-6008.	5.2	11
9	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica, 2020, 105, 1879-1886.	3.5	83
10	Germline Gain-of-Function <i>JAK3</i> Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells. Blood, 2020, 136, 9-10.	1.4	9
11	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 2072-2081.	1.6	34
12	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. Journal of Clinical Oncology, 2019, 37, 3377-3391.	1.6	169
13	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood, 2019, 133, 1313-1324.	1.4	172
14	Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. Blood, 2019, 134, 292-292.	1.4	19
15	<i>NUP98â€BPTF</i> gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. Genes Chromosomes and Cancer, 2018, 57, 311-319.	2.8	18
16	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood, 2018, 132, 264-276.	1.4	70
17	Selective Tâ€cell depletion targeting <scp>CD</scp> 45 <scp>RA</scp> reduces viremia and enhances early Tâ€cell recovery compared with <scp>CD</scp> 3â€targeted Tâ€cell depletion. Transplant Infectious Disease, 2018, 20, e12823.	1.7	46
18	Acute Undifferentiated Leukemia and Mixed-Phenotype Acute Leukemias. , 2018, , 481-487.e1.		0

#	Article	IF	CITATIONS
19	Precursor Lymphoid Neoplasms. , 2018, , 467-480.e1.		Ο
20	Mixed-phenotype acute leukemia, T/megakaryoblastic. Blood, 2018, 132, 2418-2418.	1.4	4
21	The Comparative Sensitivity of Immunohistochemical Markers of Megakaryocytic Differentiation in Acute Megakaryoblastic Leukemia. American Journal of Clinical Pathology, 2018, 150, 461-467.	0.7	11
22	Traumatic and Bloody Lumbar Puncture at Diagnosis in Children with Acute Lymphoblastic Leukemia: A St. Jude Total XV and Total XVI Cohort Study. Blood, 2018, 132, 1380-1380.	1.4	0
23	CD30 Expression in Pediatric Neoplasms, Study of 585 Cases. Pediatric and Developmental Pathology, 2017, 20, 191-196.	1.0	10
24	<i>γδ</i> T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Discussion of Two Pediatric Cases and Its Distinction from Other Mature <i>γδ</i> T-Cell Malignancies. Case Reports in Hematology, 2017, 2017, 1-7.	0.4	6
25	BCL-W has a fundamental role in B cell survival and lymphomagenesis. Journal of Clinical Investigation, 2017, 127, 635-650.	8.2	44
26	Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: A Children's Oncology Group report Journal of Clinical Oncology, 2017, 35, 10515-10515.	1.6	3
27	Adult T-cell leukemia/lymphoma. Revista Da Associação Médica Brasileira, 2016, 62, 691-700.	0.7	19
28	Metachronous T-Lymphoblastic Lymphoma and Burkitt Lymphoma in a Child With Constitutional Mismatch Repair Deficiency Syndrome. Pediatric Blood and Cancer, 2016, 63, 1454-1456.	1.5	4
29	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology, 2016, 34, 4094-4101.	1.6	93
30	Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study. Clinical Cancer Research, 2016, 22, 6247-6255.	7.0	22
31	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
32	LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. Journal of Clinical Investigation, 2016, 126, 1267-1281.	8.2	67
33	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 2015, 126, 2896-2899.	1.4	76
34	Atypical cutaneous γδT cell proliferation with morphologic features of lymphoma but with clinical features and course of <scp>PLEVA</scp> or lymphomatoid papulosis. Journal of Cutaneous Pathology, 2015, 42, 1012-1017.	1.3	15
35	Perinatal Hematology. , 2015, , 257-274.		0
36	Identification of patients with post-induction CNS 2 status and outcomes in acute lymphoblastic leukemia Journal of Clinical Oncology, 2015, 33, 10033-10033.	1.6	0

#	Article	IF	CITATIONS
37	Embryonic and Fetal Red Blood Cell Development. , 2014, , 2352-2357.		1
38	Pathogenesis of Pediatric Acute Lymphoblastic Leukemias. , 2014, , 1749-1758.		0
39	Cutaneous extranodal natural killer/T-cell lymphoma:ÂA comparative clinicohistopathologic andÂsurvival outcome analysis of 45 cases according toÂthe primary tumor site. Journal of the American Academy of Dermatology, 2014, 70, 1002-1009.	1.2	44
40	Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1224-1228.	2.0	10
41	Pediatric MLBL: challenges remain. Blood, 2013, 121, 245-246.	1.4	2
42	Intestinal Î <sup>3</sup> δT-cell lymphomas are most frequently of type II enteropathy-associated T-cell type. Human Pathology, 2013, 44, 1131-1145.	2.0	19
43	Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood, 2013, 121, 4925-4929.	1.4	104
44	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2013, 121, 2715-2724.	1.4	206
45	Platelets lacking PIP5KlÎ <sup>3</sup> have normal integrin activation but impaired cytoskeletal-membrane integrity and adhesion. Blood, 2013, 121, 2743-2752.	1.4	20
46	Detection of Leukemic Lymphoblasts in CSF Is Instrument-Dependent. American Journal of Clinical Pathology, 2012, 137, 795-799.	0.7	6
47	Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17573-17578.	7.1	108
48	α-Hemoglobin-stabilizing Protein Is a Sensitive and Specific Marker of Erythroid Precursors. American Journal of Surgical Pathology, 2012, 36, 1538-1547.	3.7	18
49	Extranodal NK/T-cell Lymphoma, Nasal Type, Includes Cases of Natural Killer Cell and αβ, γδ, and αβ/γδT-cell Origin. American Journal of Surgical Pathology, 2012, 36, 481-499.	3.7	190
50	Self-Renewing Endodermal Progenitor Lines Generated from Human Pluripotent Stem Cells. Cell Stem Cell, 2012, 10, 371-384.	11.1	190
51	G Protein βγ-Subunit Signaling Mediates Airway Hyperresponsiveness and Inflammation in Allergic Asthma. PLoS ONE, 2012, 7, e32078.	2.5	20
52	NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO Journal, 2010, 29, 442-456.	7.8	132
53	Ezrin Is Highly Expressed in Early Thymocytes, but Dispensable for T Cell Development in Mice. PLoS ONE, 2010, 5, e12404.	2.5	8
54	miR-451 protects against erythroid oxidant stress by repressing 14-3-3ζ. Genes and Development, 2010, 24, 1620-1633.	5.9	192

#	Article	IF	CITATIONS
55	Percentage of γδT Cells in Panniculitis by Paraffin Immunohistochemical Analysis. American Journal of Clinical Pathology, 2009, 131, 820-826.	0.7	49
56	Lymphocytic vasculitis involving the central nervous system occurs in patients with Xâ€linked lymphoproliferative disease in the absence of Epstein–Barr virus infection. Pediatric Blood and Cancer, 2009, 53, 1120-1123.	1.5	32
57	Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. British Journal of Haematology, 2009, 145, 101-106.	2.5	151
58	A robust xenotransplantation model for acute myeloid leukemia. Leukemia, 2009, 23, 2109-2117.	7.2	113
59	ALK Expression in Rhabdomyosarcomas: Correlation with Histologic Subtype and Fusion Status. Pediatric and Developmental Pathology, 2009, 12, 275-283.	1.0	56
60	Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. Blood, 2009, 113, 3577-3584.	1.4	44
61	Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta Tâ€cell lymphoma and occult cirrhosis. American Journal of Hematology, 2008, 83, 593-595.	4.1	23
62	Loss of PIP5KIÎ <sup>2</sup> demonstrates that PIP5KI isoform-specific PIP <sub>2</sub> synthesis is required for IP <sub>3</sub> formation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14064-14069.	7.1	47
63	γc-Signaling Cytokines Induce a Regulatory T Cell Phenotype in Malignant CD4+ T Lymphocytes. Journal of Immunology, 2008, 181, 2506-2512.	0.8	56
64	Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood, 2008, 111, 705-714.	1.4	68
65	Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. Blood, 2008, 111, 3802-3812.	1.4	14
66	Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood, 2008, 112, 4503-4506.	1.4	117
67	An erythroid chaperone that facilitates folding of α-globin subunits for hemoglobin synthesis. Journal of Clinical Investigation, 2007, 117, 1856-1865.	8.2	96
68	A Potential Screening Tool for IPEX Syndrome. Pediatric and Developmental Pathology, 2007, 10, 98-105.	1.0	43
69	Pediatric Primary Bone Lymphoma-Diffuse Large B-Cell Lymphoma: Morphologic and Immunohistochemical Characteristics of 10 Cases. American Journal of Clinical Pathology, 2007, 127, 47-54.	0.7	0
70	Mediastinal Adenopathy, Lung Infiltrates, and Hemophagocytosis: Unusual Manifestation of Pediatric Anaplastic Large Cell Lymphoma: Report of Two Cases. American Journal of Clinical Pathology, 2007, 127, 458-464.	0.7	0
71	The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood, 2006, 107, 1149-1155.	1.4	165
72	Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood, 2006, 108, 1965-1971.	1.4	82

#	Article	IF	CITATIONS
73	Primary Non-Hodgkin's Lymphoma of Bone in Children. Journal of Bone and Joint Surgery - Series A, 2006, 88, 583.	3.0	40
74	Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood, 2005, 105, 2443-2448.	1.4	151
75	Early molecular detection of central nervous system relapse in a child with systemic anaplastic large cell lymphoma: Case report and review of the literature. Pediatric Blood and Cancer, 2005, 44, 400-406.	1.5	6
76	Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Experimental Cell Research, 2005, 305, 343-354.	2.6	73
77	Tie2-Cre–Induced Inactivation of a Conditional Mutant Nf1 Allele in Mouse Results in a Myeloproliferative Disorder that Models Juvenile Myelomonocytic Leukemia. Pediatric Research, 2004, 55, 581-584.	2.3	40
78	Immunohistochemical Detection of <i>Aspergillus</i> Species in Pediatric Tissue Samples. American Journal of Clinical Pathology, 2004, 121, 18-25.	0.7	40
79	Identification of Cyclin D3 as a Direct Target of E2A Using DamID. Molecular and Cellular Biology, 2004, 24, 8790-8802.	2.3	29
80	Cell Division Rates of Primary Human Precursor B Cells in Culture Reflect In Vivo Rates. Stem Cells, 2004, 22, 1111-1120.	3.2	39
81	Pulmonary Hypertension Complicating Bone Marrow Transplantation for Idiopathic Myelofibrosis. Journal of Pediatric Hematology/Oncology, 2004, 26, 393-397.	0.6	24
82	Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. Blood, 2004, 104, 1833-1840.	1.4	50
83	The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia–like disease by bcr/abl. Blood, 2002, 99, 2957-2968.	1.4	105
84	Hybrid HIV/MSCV LTR Enhances Transgene Expression of Lentiviral Vectors in Human CD34+Hematopoietic Cells. Stem Cells, 2001, 19, 236-246.	3.2	34
85	Promotion of Cell Cycle Progression by Basic Helix-Loop-Helix E2A. Molecular and Cellular Biology, 2001, 21, 6346-6357.	2.3	46
86	Hodgkin's disease presenting as a submental mass. Journal of Oral and Maxillofacial Surgery, 1999, 57, 1363-1366.	1.2	3
87	Dispensability of the Actin-Binding Site and Spectrin Repeats for Targeting Sarcomeric α-Actinin into Maturing Z Bandsin Vivo:Implications forin VitroBinding Studies. Developmental Biology, 1998, 199, 291-308.	2.0	30
88	Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant. Journal of Experimental Medicine, 1998, 187, 1995-2007.	8.5	94
89	Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO Journal, 1997, 16, 6151-6161.	7.8	521
90	Unanticipated temporal and spatial effects of sarcomeric αâ€actinin peptides expressed in PtK2 cells. Cytoskeleton, 1997, 38, 54-74.	4.4	0

#	Article	IF	CITATIONS
91	E47 activates the Ig-heavy chain and TdT loci in non-B cells EMBO Journal, 1996, 15, 5014-5021.	7.8	91
92	Sequential appearance of muscle-specific proteins in myoblasts as a function of time after cell division: Evidence for a conserved myoblast differentiation program in skeletal muscle. Cytoskeleton, 1994, 29, 1-19.	4.4	129
93	A sarcomeric alpha-actinin truncated at the carboxyl end induces the breakdown of stress fibers in PtK2 cells and the formation of nemaline-like bodies and breakdown of myofibrils in myotubes Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9282-9286.	7.1	55
94	The vinculin/sarcomeric-alpha-actinin/alpha-actin nexus in cultured cardiac myocytes. Journal of Cell Biology, 1992, 117, 1007-1022.	5.2	113
95	G-actin pool and actin messenger RNA during development of the apical processes of the retinal pigment epithelial cells of the chick. Developmental Biology, 1992, 149, 239-246.	2.0	9
96	Phorbol esters selectively and reversibly inhibit a subset of myofibrillar genes responsible for the ongoing differentiation program of chick skeletal myotubes Molecular and Cellular Biology, 1991, 11, 4473-4482.	2.3	27
97	Autonomous Expression of the Differentiation Programs of Cells in the Cardiac and Skeletal Myogenic Lineages. Annals of the New York Academy of Sciences, 1990, 599, 158-169.	3.8	40
98	Purification of protein methylase II from human erythrocytes. Journal of Proteomics, 1983, 8, 9-14.	2.4	18
99	Microsome-dependent methylation of erythrocyte proteins by dimethylnitrosamine. Carcinogenesis, 1981, 2, 179-182.	2.8	13
100	Myelodysplastic/myeloproliferative neoplasms. , 0, , 245-252.		0
101	Hematologic abnormalities in individuals with Down syndrome. , 0, , 310-322.		2